Home Cart Sign in  
Chemical Structure| 1458-01-1 Chemical Structure| 1458-01-1

Structure of 1458-01-1

Chemical Structure| 1458-01-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1458-01-1 ]

CAS No. :1458-01-1
Formula : C6H7ClN4O2
M.W : 202.60
SMILES Code : COC(=O)C1=NC(=C(N=C1N)N)Cl
MDL No. :MFCD01928388
InChI Key :KOOBYHRLTYIPTH-UHFFFAOYSA-N
Pubchem ID :73827

Safety of [ 1458-01-1 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1458-01-1 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 6
Fraction Csp3 0.17
Num. rotatable bonds 2
Num. H-bond acceptors 4.0
Num. H-bond donors 2.0
Molar Refractivity 47.13
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

104.12 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.04
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.79
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.1
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.96
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.01
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.2

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.8
Solubility 3.19 mg/ml ; 0.0157 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.56
Solubility 0.561 mg/ml ; 0.00277 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.63
Solubility 4.72 mg/ml ; 0.0233 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.97 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.38

Application In Synthesis of [ 1458-01-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1458-01-1 ]

[ 1458-01-1 ] Synthesis Path-Downstream   1~35

  • 3
  • [ 6331-57-3 ]
  • [ 1458-01-1 ]
  • [ 146940-54-7 ]
  • 4
  • [ 168627-33-6 ]
  • [ 1458-01-1 ]
  • [ 146940-52-5 ]
  • 5
  • [ 45715-47-7 ]
  • [ 1458-01-1 ]
  • [ 146940-53-6 ]
  • 6
  • [ 1458-01-1 ]
  • [ 80364-48-3 ]
  • [ 4878-36-8 ]
YieldReaction ConditionsOperation in experiment
HMRS: molecularion calcd. for C5 H6 N4 O2, m/e 154.0491; measured m/e, 154.053. Peak at m/e 110 (for M-CO2) This material can be converted in good yield to the known methyl 3,5-diaminopyrazinoate (U.S. Pat. No. 3,313,813, Example 2) by standard procedures. It in turn can be chlorinated by sulfuryl chloride to give methyl-6-chloro-3,5-diaminopyrazinoate. 3,5-Diamino-2,6-dicarboxypyrazine is available from basic hydrolysis of 3,5-diamino-2,6-dicyanopyrazine by the following reaction: SPC8
  • 8
  • [ 67-56-1 ]
  • [ 2609-46-3 ]
  • [ 1458-01-1 ]
  • 9
  • [ 141-43-5 ]
  • [ 4023-02-3 ]
  • [ 1458-01-1 ]
  • [ 2394-67-4 ]
  • 10
  • [ 64-04-0 ]
  • [ 4023-02-3 ]
  • [ 1458-01-1 ]
  • [ 1163-46-8 ]
  • 11
  • [ 111-86-4 ]
  • [ 4023-02-3 ]
  • [ 1458-01-1 ]
  • <i>N</i>-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-<i>N</i>'-octyl-guanidine [ No CAS ]
  • 12
  • [ 111-26-2 ]
  • [ 4023-02-3 ]
  • [ 1458-01-1 ]
  • <i>N</i>-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-<i>N</i>'-hexyl-guanidine [ No CAS ]
  • 13
  • [ 13214-66-9 ]
  • [ 4023-02-3 ]
  • [ 1458-01-1 ]
  • <i>N</i>-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-<i>N</i>'-(4-phenyl-butyl)-guanidine [ No CAS ]
  • 14
  • [ 2038-57-5 ]
  • [ 4023-02-3 ]
  • [ 1458-01-1 ]
  • <i>N</i>-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-<i>N</i>'-(3-phenyl-propyl)-guanidine [ No CAS ]
  • 15
  • [ 17734-21-3 ]
  • [ 4023-02-3 ]
  • [ 1458-01-1 ]
  • <i>N</i>-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-<i>N</i>'-(5-phenyl-pentyl)-guanidine [ No CAS ]
  • 16
  • [ 17734-20-2 ]
  • [ 4023-02-3 ]
  • [ 1458-01-1 ]
  • <i>N</i>-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-<i>N</i>'-(6-phenyl-hexyl)-guanidine [ No CAS ]
  • 17
  • [ 17734-23-5 ]
  • [ 4023-02-3 ]
  • [ 1458-01-1 ]
  • <i>N</i>-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-<i>N</i>'-(8-phenyl-octyl)-guanidine [ No CAS ]
  • 18
  • [ 1458-01-1 ]
  • [ 147452-34-4 ]
  • 19
  • [ 1458-01-1 ]
  • [ 80364-54-1 ]
  • 20
  • [ 1458-01-1 ]
  • [ 345624-49-9 ]
  • 21
  • [ 1458-01-1 ]
  • [ 345219-84-3 ]
  • 22
  • [ 1458-01-1 ]
  • [ 345301-71-5 ]
  • 23
  • [ 1458-01-1 ]
  • [ 345300-33-6 ]
  • 24
  • [ 1458-01-1 ]
  • 5-(3,5-Diamino-6-chloro-pyrazin-2-yl)-4-ethyl-3-mercapto-1-methyl-4H-[1,2,4]triazol-1-ium; hydroxide [ No CAS ]
  • 25
  • [ 1458-01-1 ]
  • 4-Allyl-5-(3,5-diamino-6-chloro-pyrazin-2-yl)-3-mercapto-1-methyl-4H-[1,2,4]triazol-1-ium; hydroxide [ No CAS ]
  • 26
  • [ 1458-01-1 ]
  • anhydro-1,4-dimethyl-3-mercapto-5-(3,5-diamino-6-chloropyrazinyl)-1,2,4-triazolium hydroxide [ No CAS ]
  • 27
  • [ 1458-01-1 ]
  • 5-(3,5-Diamino-6-chloro-pyrazin-2-yl)-3-mercapto-1-methyl-4-phenyl-4H-[1,2,4]triazol-1-ium; hydroxide [ No CAS ]
  • 28
  • [ 1458-01-1 ]
  • 5-(3,5-Diamino-6-chloro-pyrazin-2-yl)-4-(4-fluoro-phenyl)-3-mercapto-1-methyl-4H-[1,2,4]triazol-1-ium; hydroxide [ No CAS ]
  • 29
  • [ 1458-01-1 ]
  • [ 79998-20-2 ]
  • 30
  • [ 1458-01-1 ]
  • [ 25658-64-4 ]
  • 31
  • [ 1458-01-1 ]
  • [ 26865-25-8 ]
  • 32
  • [ 1458-01-1 ]
  • [ 33249-57-9 ]
  • 33
  • [ 1458-01-1 ]
  • [ 1458-19-1 ]
YieldReaction ConditionsOperation in experiment
100% With formic acid; triethylamine;tetrakis(triphenylphosphine) palladium(0); In tetrahydrofuran; at 0 - 125℃; for 12h; Preparation Example AA-1. 3,5-Diamino-pyrazine-2-carboxylic acid methyl ester To a solution of <strong>[1458-01-1]3,5-diamino-6-chloro-pyrazine-2-carboxylic acid methyl ester</strong> (8.00g, 39.5mmol) in tetrahydrofuran (150mL) were added tetrakis(triphenylphosphine)palladium(0) (2.28g, 1.98mmol), formic acid (2.24mL, 59.3mmol) and triethylamine (16.5mL, 119mmol) at 0°C under nitrogen atmosphere, then, the solution was stirred at 125°C for 12 hours. The reaction solution was cooled to room temperature, and a solid precipitated. This solid was collected by filtration, and the title compound (10.7g, quantitatively) was obtained as a crude product of a white solid. 1H-NMR Spectrum (DMSO-d6) delta (ppm) : 3.70(3H, s), 6.95(2H, brs), 7.21 (1H, s).
100% With formic acid; triethylamine;tetrakis(triphenylphosphine) palladium(0); In tetrahydrofuran; at 0 - 125℃; for 12h; To a solution of <strong>[1458-01-1]3,5-diamino-6-chloro-pyrazine-2-carboxylic acid methyl ester</strong> (8.00g, 39.5mmol) in tetrahydrofuran (150mL) were added tetrakis(triphenylphosphine)palladium(0) (2.28g, 1.98mmol), formic acid (2.24mL, 59.3mmol) and triethylamine (16.5mL, 119mmol) at 0°C under nitrogen atmosphere, then, the solution was stirred at 125°C for 12 hours. The reaction solution was cooled to room temperature, and a solid precipitated. This solid was collected by filtration, and the title compound (10.7g, quantitatively) was obtained as a crude product of a white solid. 1H-NMR Spectrum (DMSO-d6) delta(ppm) : 3.70(3H, s), 6.95(2H, brs), 7.21 (1 H, s).
  • 34
  • [ 1458-01-1 ]
  • [ 109-81-9 ]
  • [ 119646-69-4 ]
YieldReaction ConditionsOperation in experiment
In tetrahydrofuran; (1) A mixture of 20 g (99.0 mmol) of methyl 3,5-diamino-6-chloropyrazine-2-carboxylate (see U.S. Pat. No. 4,029,816 for an example of how to obtain this material) and 17 g (230.0 mmol) of N-methylethylenediamine was heated at reflux under an inert atmosphere for 30 hours. The rection mixture was cooled to ambient temperature and the solid was dissolved in 100 ml of tetrahydrofuran. The solution was filtered and evaporated. The residue was crystallized from 2-propanol. There was obtained 15.0 g (61.2 mmol, 61percent) of 3,5-diamino-6-chloro-N-(2-methylaminoethyl)pyrazine-2-carboxamide; mp 142.5°-143° C. Analysis calculated for; C8 H13 ClN6 O: C, 39.27; H, 5.35; N, 34.35; Found: C, 39.28; H, 5.26; N, 34.55.
  • 35
  • [ 1458-01-1 ]
  • [ 87663-03-4 ]
YieldReaction ConditionsOperation in experiment
In ethylenediamine; (b) A mixture of 2.0 g (10.0 mmol) of methyl 3,5-diamino-6-chloropyrazine-2-carboxylate and 13.5 g (22.6 mmol) of ethylene diamine was allowed to stand for 3 days at ambient temperature. The excess amine was evaporated and the residue was crystallized from ethanol. There was obtained 1.38 g (5.9 mmol, 59percent) of 3,5-diamino-6-chloro-N-(2-aminoethyl)pyrazine-2-carboxamide: mp 173°-174° C. Analysis calculated for C7 H11 ClN6 O: C, 36.45: N, 4.81; N, 36.44; Found: C, 36.50; N, 4.71; N, 36.22
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1458-01-1 ]

Chlorides

Chemical Structure| 1458-03-3

A207024 [1458-03-3]

Methyl 3-amino-6-chloropyrazine-2-carboxylate

Similarity: 0.90

Chemical Structure| 1458-18-0

A108171 [1458-18-0]

Methyl 3-amino-5,6-dichloropyrazine-2-carboxylate

Similarity: 0.88

Chemical Structure| 2727-13-1

A172057 [2727-13-1]

3-Amino-6-chloropyrazine-2-carboxylic acid

Similarity: 0.84

Chemical Structure| 23611-75-8

A134965 [23611-75-8]

Methyl 6-chloropyrazine-2-carboxylate

Similarity: 0.77

Chemical Structure| 33332-25-1

A142392 [33332-25-1]

Methyl 5-chloropyrazine-2-carboxylate

Similarity: 0.77

Esters

Chemical Structure| 1458-03-3

A207024 [1458-03-3]

Methyl 3-amino-6-chloropyrazine-2-carboxylate

Similarity: 0.90

Chemical Structure| 1458-18-0

A108171 [1458-18-0]

Methyl 3-amino-5,6-dichloropyrazine-2-carboxylate

Similarity: 0.88

Chemical Structure| 16298-03-6

A208317 [16298-03-6]

Methyl 2-aminopyrazine-3-carboxylate

Similarity: 0.78

Chemical Structure| 1458-20-4

A102926 [1458-20-4]

Methyl 3,5-diamino-6-bromopyrazine-2-carboxylate

Similarity: 0.78

Chemical Structure| 33332-25-1

A142392 [33332-25-1]

Methyl 5-chloropyrazine-2-carboxylate

Similarity: 0.77

Amines

Chemical Structure| 1458-03-3

A207024 [1458-03-3]

Methyl 3-amino-6-chloropyrazine-2-carboxylate

Similarity: 0.90

Chemical Structure| 1458-18-0

A108171 [1458-18-0]

Methyl 3-amino-5,6-dichloropyrazine-2-carboxylate

Similarity: 0.88

Chemical Structure| 2727-13-1

A172057 [2727-13-1]

3-Amino-6-chloropyrazine-2-carboxylic acid

Similarity: 0.84

Chemical Structure| 16298-03-6

A208317 [16298-03-6]

Methyl 2-aminopyrazine-3-carboxylate

Similarity: 0.78

Chemical Structure| 1458-20-4

A102926 [1458-20-4]

Methyl 3,5-diamino-6-bromopyrazine-2-carboxylate

Similarity: 0.78

Related Parent Nucleus of
[ 1458-01-1 ]

Pyrazines

Chemical Structure| 1458-03-3

A207024 [1458-03-3]

Methyl 3-amino-6-chloropyrazine-2-carboxylate

Similarity: 0.90

Chemical Structure| 1458-18-0

A108171 [1458-18-0]

Methyl 3-amino-5,6-dichloropyrazine-2-carboxylate

Similarity: 0.88

Chemical Structure| 2727-13-1

A172057 [2727-13-1]

3-Amino-6-chloropyrazine-2-carboxylic acid

Similarity: 0.84

Chemical Structure| 16298-03-6

A208317 [16298-03-6]

Methyl 2-aminopyrazine-3-carboxylate

Similarity: 0.78

Chemical Structure| 1458-20-4

A102926 [1458-20-4]

Methyl 3,5-diamino-6-bromopyrazine-2-carboxylate

Similarity: 0.78